Chem

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

Retrieved on: 
Monday, April 8, 2024
PARP1, Chem, MDA, Drug, Patient, Cancer, IND, Abstract, AACR, Survivor, DRF, Clinical trial, PARP, MOA, Xenotransplantation, Safety, Biology, San Diego Convention Center, Drug discovery, Medicine, Annual general meeting, PCC, Pharmaceutical industry

"After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.

Key Points: 
  • "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.
  • Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients."
  • The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage.
  • The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA.

X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy

Retrieved on: 
Tuesday, April 2, 2024
Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Machine learning, Informatics, Computational chemistry, Chem, Creativity, Drug discovery

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.

Key Points: 
  • X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.
  • Dr. Davis brings extensive experience in the areas of data strategy, informatics, computational chemistry and software solutions in drug discovery.
  • The addition of Dr. Davis to X-Chem’s executive team bolsters X-Chem’s strategy of leveraging its data generation platforms and deploying digitized drug discovery solutions to its clients.
  • “I am so excited to see Erin join the amazing team we have here at X-Chem,” said Karen Lackey, chief executive officer.

Solvay Strengthens Its Customer Relationships and Reduces Its Carbon Footprint with Esker

Retrieved on: 
Tuesday, March 26, 2024
Software, Payments, Finance, Artificial Intelligence, Professional Services, Technology, Apps, Applications, Fintech, Automation, Chem, ERP, Carbon, Supply, Supply chain, Paper, Customer service, Sales

This worldwide deployment has enabled Solvay to considerably reduce its order processing time while significantly reducing its carbon footprint.

Key Points: 
  • This worldwide deployment has enabled Solvay to considerably reduce its order processing time while significantly reducing its carbon footprint.
  • Faced with the functional, technical and financial limitations of its existing systems, Solvay accelerated its digital transformation three years ago and implemented Esker Order Management.
  • This aligns perfectly with the Solvay Way, which encompasses our commitment to sustainability,” said Sonia Boibessot, eBusiness Process Specialist at Solvay.
  • “This has enabled the Customer Service team to concentrate on higher-value tasks, such as offering customer support.

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Retrieved on: 
Tuesday, March 5, 2024
Infection, MCM, NIAID, NIH, ARS, TEL, FDA, SPHK2, Food, Acute radiation syndrome, RNCP, Bronchiolitis obliterans, Radiation, Mustard gas, HHS, Administration, COVID-19, Chem, ASPR, CCRP, Fibrosis, Acute respiratory distress syndrome, Development, White lung, Opaganib, Pharmaceutical industry

The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.

Key Points: 
  • The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.
  • "With the alarming increase in global geo-political instability, the opportunity to evaluate opaganib as a potential vital protective agent against chemical attack is inspiring.
  • "Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure.
  • Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute for use against potential chemical weapon attack, if approved by the FDA.

Scientific Recognition for Golem Network-Powered Project Simulating the Origins of Life on Earth

Retrieved on: 
Thursday, January 25, 2024
Environment, Life, CPO, Chem, Renewable energy

ZUG, Switzerland, Jan. 25, 2024 /PRNewswire/ -- Golem Network, the decentralized computing platform and pioneer in the realm of DePIN (Decentralized Physical Infrastructure Networks), is excited to announce a key achievement in collaboration with the scientific software company, Allchemy. The scientific project powered by Golem Network aimed at discovering the origins of life on Earth has been recognized and published by the prestigious scientific journal Chem.

Key Points: 
  • The scientific project powered by Golem Network aimed at discovering the origins of life on Earth has been recognized and published by the prestigious scientific journal Chem .
  • Previously, Allchemy unveiled a compilation of 50,000 molecules believed to have emerged during the origins of life on Earth, a scientific study published in Science magazine .
  • The collaborative nature of Golem's platform allowed individuals, irrespective of geographical location, to play an essential role in simulating how life on Earth began.
  • "The scientific community recognition of a project powered by the Golem Network marks a significant milestone," said Paweł Burgchardt, CPO at Golem Network.

Scientific Recognition for Golem Network-Powered Project Simulating the Origins of Life on Earth

Retrieved on: 
Thursday, January 25, 2024
Environment, Life, CPO, Chem, Renewable energy

ZUG, Switzerland, Jan. 25, 2024 /PRNewswire/ -- Golem Network, the decentralized computing platform and pioneer in the realm of DePIN (Decentralized Physical Infrastructure Networks), is excited to announce a key achievement in collaboration with the scientific software company, Allchemy. The scientific project powered by Golem Network aimed at discovering the origins of life on Earth has been recognized and published by the prestigious scientific journal Chem.

Key Points: 
  • The scientific project powered by Golem Network aimed at discovering the origins of life on Earth has been recognized and published by the prestigious scientific journal Chem .
  • Previously, Allchemy unveiled a compilation of 50,000 molecules believed to have emerged during the origins of life on Earth, a scientific study published in Science magazine .
  • The collaborative nature of Golem's platform allowed individuals, irrespective of geographical location, to play an essential role in simulating how life on Earth began.
  • "The scientific community recognition of a project powered by the Golem Network marks a significant milestone," said Paweł Burgchardt, CPO at Golem Network.

Meridian's E-Chem innovation will be featured at the 2024 Transportation Research Board Annual Meeting in Washington, D.C.

Retrieved on: 
Tuesday, January 9, 2024
Carbon footprint, BOND, Urethane, GCS, Dots, TRB, 34th Street (Manhattan), Chem, SXT, Noetics, Longevity, Use, Road

CHARLOTTE, N.C., Jan. 9, 2024 /PRNewswire-PRWeb/ -- When it comes to new products, 2023 has been a very productive year at E-Chem. The company, part of the Infrastructure Division of Meridian Adhesives Group, will be rolling out four new products at the TRB with a host of benefits.

Key Points: 
  • CHARLOTTE, N.C., Jan. 9, 2024 /PRNewswire-PRWeb/ -- When it comes to new products, 2023 has been a very productive year at E-Chem.
  • "We believe that these new offerings will get wide attention among engineers, specifiers, GCs, and DOTs across the country," explained Ray Breer, Sales Director at E-Chem.
  • "Each is designed to markedly improve the performance and longevity of concrete in the transportation sector."
  • To learn more about these and other new roadway solutions developed by E-Chem, visit their booth 544 at the TRB Annual Meeting, January 7-11, in Washington D.C., or go to https://e-chem.net

X‑Chem Transitions Executives into New Roles, Appoints New Chief Executive Officer

Retrieved on: 
Thursday, January 4, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Drug discovery, Multimedia, DEL, Chem, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240104597901/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240104597901/en/
    X-Chem executives transition into new roles: Karen Lackey (left) will serve as Chief Executive Officer and Matt Clark (right) becomes X-Chem President and Chief Scientific Officer.
  • (Photo: Business Wire)
    Karen Lackey , currently Chief Scientific Officer, will transition to the role of Chief Executive Officer.
  • Current X-Chem Chief Executive Officer Matthew Clark will transition to the role of President and Chief Scientific Officer.
  • Together, we can continue to bring incredible innovation to drug discovery, unlocking the biological problems of the future to the benefit of patients.”

Rumi Scientific Announces Partnership with X-Chem for Development of Lead Candidate in Huntington’s Disease

Retrieved on: 
Tuesday, December 5, 2023
Biology, Partnership, Drug discovery, BRD9, Disease, Brain, Chem, Doctor of Philosophy, HD, Observation, Machine learning, Phenotype

RUMI Scientific has identified bromodomain 9 (BRD9), an epigenetic reader, as a novel therapeutic target for HD with the potential to modify the disease's progression.

Key Points: 
  • RUMI Scientific has identified bromodomain 9 (BRD9), an epigenetic reader, as a novel therapeutic target for HD with the potential to modify the disease's progression.
  • A key result from these studies is that lowering of BRD9 levels can restore striatal volume a significant observation demonstrating disease modifying potential.
  • "We are excited to be partnering with RUMI Scientific in their pursuit of a lead candidate iBRD9 for HD” said Matt Clark, Ph.D., Chief Executive Officer of X-Chem.
  • “RUMI Scientific's profound understanding of HD biology and their innovative drug discovery platform make them an ideal partner.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.